Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade

This study is testing whether adding two drugs — bevacizumab (a blood vessel-blocking drug) and low-dose cyclophosphamide (a chemotherapy drug given in small daily doses) — can help people with non-small cell lung cancer or skin melanoma whose disease progressed after immunotherapy. **You may be eligible if...** - You are 18 or older - You have advanced non-small cell lung cancer or cutaneous (skin) melanoma with distant spread - Your cancer progressed after receiving immunotherapy (anti-PD-1 or anti-PD-L1 drugs) - For lung cancer: you have no EGFR, ALK, ROS1, or RET gene mutations - Your overall health is good enough (ECOG score 0–2) **You may NOT be eligible if...** - You have serious heart disease, recent stroke, or uncontrolled high blood pressure - You have had another cancer in the past 2 years (with some exceptions) - You are pregnant or breastfeeding - You have active autoimmune disease or significant bleeding risk Talk to your doctor to see if this trial is right for you.